Are There Therapies Targeting Histone Modifications?
Targeting histone modifications is a promising therapeutic strategy for cancer. Histone deacetylase inhibitors (HDACi) and histone methyltransferase inhibitors (HMTi) are two classes of drugs that modulate histone modifications. HDAC inhibitors, such as vorinostat and romidepsin, have shown efficacy in treating certain hematologic malignancies by reactivating silenced genes. Similarly, inhibitors of histone methyltransferases, like EZH2 inhibitors, are being explored for their potential to reverse aberrant gene silencing in cancers.
